Thanks very much, Chair.
Certainly I have a difference of opinion with respect to Mr. Julian. I suspect we will need a ruling from you on this, Chair.
The thing I will agree with Mr. Julian on is that during the testimony, we heard about the powers of recall and the importance thereof, and I will also agree with him—I know you will find this shocking, but I will agree with him again—that we heard great acceptance of this within the industry.
What I would like to point out to you, though, Chair, with respect to admissibility is that, in essence, Bill C-368 changes the definition of a therapeutic product, meaning that a natural health product is not considered a therapeutic product by the overall scope of this bill. When you look at the Food and Drugs Act cited in Mr. Julian's amendment, you see that it goes on to talk about a therapeutic product.
In my mind, those two things are diametrically opposed. It becomes very difficult to exclude natural health products from being a therapeutic product but then cite regulations inside the Food and Drugs Act that call it a therapeutic product. That is, in my mind, as I said, a binary decision. You can't be and not be a therapeutic product at the same time.
That would be the difficulty that I would have, and I would go on to suggest that there perhaps are—again, directly contradicting Dr. Powlowski—more elegant ways proposed by Mr. Thériault to allow the minister to have those abilities of recall, etc., that we talked about.
In essence, the amendments would specifically come back to two things: the ability to recall products—which, again, we heard already exists—and strengthening that ability. I don't think there's going to be any argument against that.
The second part of it, of course, is the removal of nicotine-containing products from the definition of natural health products.
I think that when we begin to muddy the waters of the definition of a therapeutic product by allowing it to be a therapeutic product in one sense but not in another, it is going to create significant difficulties with the original omnibus bill that was presented by the NDP-Liberal government back in the spring, because the definition of a therapeutic product, a natural health product, becoming in essence a therapeutic product would then allow all of the other changes that come about thereafter, meaning the cost recovery program and the labelling changes as well.
As I said, in my mind, those two things are diametrically opposed. Given that the principle of the bill is to move natural health products out of the therapeutic product realm, the admissibility rules would state that the most common rules of admissibility are related to the principle of the bill and:
The principle of the bill is the object or purpose which the bill seeks to achieve. The principle of the bill is fixed when the bill is adopted at second reading. Any amendment contrary to the principle of the bill is inadmissible.
I think that if the real principle of the bill is unclear, we have a unique situation here. If it's unclear in writing, we could ask the drafter of the bill what the principle of the bill is, and I think it would be very clear that moving all natural health products away from the definition of a therapeutic product is really the principle of this bill and therefore makes NDP-1 inadmissible as an amendment.
I'll say it one more time. That doesn't mean that we don't support that type of movement, just that the NDP-1 amendment has to be deemed inadmissible by you.
Thank you, Chair.